Ferric Citrate 1 GM Oral Tablet [AURYXIA] + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
69
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Anemia, Iron Deficiency
Conditions
Anemia, Iron Deficiency, Hyperphosphatemia, Renal Insufficiency, Chronic, Renal Anemia, Disease Progression, Cardiovascular, Iron
Trial Timeline
Mar 30, 2022 โ Jan 24, 2024
NCT ID
NCT05085275About Ferric Citrate 1 GM Oral Tablet [AURYXIA] + Placebo
Ferric Citrate 1 GM Oral Tablet [AURYXIA] + Placebo is a phase 3 stage product being developed by Akebia Therapeutics for Anemia, Iron Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT05085275. Target conditions include Anemia, Iron Deficiency, Hyperphosphatemia, Renal Insufficiency, Chronic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05085275 | Phase 3 | Completed |
Competing Products
20 competing products in Anemia, Iron Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aranespยฎ | Amgen | Approved | 84 |
| KER-047 | Keros Therapeutics | Phase 2 | 44 |
| LY2787106 | Eli Lilly | Phase 1 | 33 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| epoetin beta + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| recombinant human erythropoietin + recombinant human erythropoietin placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| recombinant human erythropoietin + recombinant human erythropoietin | Chugai Pharmaceutical | Phase 3 | 77 |
| darbepoetin alfa | Amgen | Phase 3 | 76 |
| Prasugrel | Daiichi Sankyo | Phase 1 | 33 |
| Prasugrel + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| Roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| Alefacept | Astellas Pharma | Phase 1 | 33 |
| Roxadustat | Astellas Pharma | Phase 2 | 52 |
| roxadustat | Astellas Pharma | Phase 1 | 33 |
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 77 |
| Roxadustat | Astellas Pharma | Pre-clinical | 23 |
| Roxadustat + Epoetin Alfa | Astellas Pharma | Phase 3 | 77 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |